Trial · NCT07154797
Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
NCT07154797, Not applicable, Completed, SpyGlass Pharma, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma. Trials, record NCT07154797. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07154797
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
- NCT number
- NCT07154797
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- SpyGlass Pharma, Inc.
- Conditions
- Cataract, Ocular Hypertension, Glaucoma
- Interventions
- Bimatoprost Implant System / IOL Combination
- First posted
- 2025-09-04
- Last updated
- 2025-09-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Unmedicated eyes with IOP reduction of ≥20% from Baseline to the Month 6 | From Baseline until the end of post-operative follow-up at Month 6 | The proportion of unmedicated eyes with IOP reduction of ≥ 20% from Baseline to the Month 6 exam. |
| Secondary | Mean change in unmedicated IOP from Baseline to Month 6 | From Baseline until the end of post-operative follow-up at Month 6 | Mean change in unmedicated IOP (mmHg) from Baseline to Month 6 |
| Secondary | Number of topical glaucoma medications | From Screening until the end of post-operative follow-up at Month 6 | Number of topical glaucoma medications used at Screening compared to Month 6 |
| Other | Adverse Events | From Screening to the end of post-operative follow-up at Month 6 | All adverse events occurring during the conduct of this study will be captured and reported. |
| Other | Supplementary Safety Parameter - BCDVA | From Screening to the end of post-operative follow-up at Month 6 | Best Corrected Distance Visual Acuity (snellen) |
| Other | Supplementary Safety Parameter - Slit Lamp Examination | From Screening to the end of post-operative follow-up at Month 6 | Slit Lamp Examination Findings |
| Other | Supplementary Safety Parameter - Fundus Examination | From Screening until the end of post-operative follow-up at Month 6 | Dilated Fundus Examination Findings |
| Other | Supplementary Safety Parameter - Pachymetry | From Screening until the end of post-operative follow-up at Month 6 | Mean central corneal thickness (micrometers) |
| Other | Supplementary Safety Parameter - Specular Microscopy | From Baseline until the end of post-operative follow-up at Month 6 | Endothelial cell density (cells per square millimeter) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41621045 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07154797
GET https://conductscience.org/api/trials/v1/NCT07154797/registered